Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Moderna, Inc. filed a Form 3 for Banque Soria Ester, who serves as Chief Commercial Officer. This is an initial statement of beneficial ownership that establishes her status as a reporting insider. The filing does not list any stock or option transactions, so it functions mainly as a baseline disclosure of her role under insider reporting rules.
Moderna, Inc. (MRNA) reported a Form 144 notice indicating securities were sold or to be sold under Rule 144 related to a stock option exercise on 06/18/2026. The filing lists 25,770 shares tied to the June 18, 2026 exercise and a separate sale of 36,759 shares on 05/08/2026, with dollar amounts shown in the filing. The transaction method for the exercise is listed as cash and the broker-dealer noted is Fidelity Brokerage Services LLC.
Moderna, Inc. president Stephen Hoge exercised stock options and sold shares in a pre-planned transaction. On June 15, 2026, he exercised options for a total of 53,336 shares of common stock at an exercise price of $19.15 per share, then sold 53,336 shares in an open-market transaction at an average price of $51.37 per share.
After these transactions, Hoge holds 1,483,848 shares of Moderna common stock directly, plus indirect holdings of 151,933 shares through a trust for his spouse and children and 4,116 shares through Valhalla, LLC. The filing notes that the sale was made under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating it was pre-scheduled.
Moderna, Inc. submitted a Form 144 notice relating to the proposed sale of 53,336 shares of Common Stock on 06/15/2026, identified as a Stock Option Exercise with cash settlement. The filing shows a prior sale by Stephen Hoge of 53,336 shares on 05/15/2026 for $2,581,462.40.
The filing lists a purchaser/recipient line for Fidelity Brokerage Services LLC and numeric values of $2,739,870.32 and 396,786,259 appearing in the excerpt; the document links the shares and exercise method to the issuer and cash settlement.
Moderna, Inc. Chief Legal Officer Shannon Thyme Klinger reported a mix of option exercises, RSU vesting, tax withholding, and a small stock sale. She exercised stock options and restricted stock units to acquire a total of 15,269 shares of common stock.
On one date, 3,471 shares of common stock were sold at $50.00 per share in an open-market transaction made under a pre-arranged Rule 10b5-1 trading plan. Separately, 5,705 shares were withheld to cover tax obligations related to RSU vesting, which is not an open-market sale.
Moderna, Inc.’s Chief Financial Officer James M. Mock reported routine equity compensation activity. On June 5, 2026, 11,798 restricted stock units converted into the same number of common shares on a one-for-one basis. To cover tax withholding obligations tied to this vesting, 5,705 common shares were withheld rather than sold on the open market. After these transactions, he directly holds 65,687 shares of common stock and 117,976 restricted stock units, reflecting ongoing equity-based compensation rather than discretionary buying or selling.
Moderna, Inc. Chief Financial Officer James M. Mock reported routine equity compensation activity involving restricted stock units and related tax withholding. He exercised 2,475 restricted stock units, which convert into common stock on a one-for-one basis, adding the same number of common shares.
To cover tax withholding obligations on this vesting, 1,197 common shares were withheld, at a value of $47.19 per share, rather than sold in the open market. Following these transactions, Mock directly holds 60,791 shares of common stock and 27,230 restricted stock units subject to future vesting under the disclosed schedule.
Moderna, Inc. Chief Legal Officer Shannon Thyme Klinger reported routine equity compensation activity. On June 1, 2026, restricted stock units (RSUs) converted into 2,165 shares of common stock on a one-for-one basis. In a related move, 1,047 common shares were withheld at $47.19 per share to satisfy tax withholding obligations in connection with the RSU vesting. These transactions reflect an exercise of derivative securities and associated tax-withholding dispositions, rather than open-market buying or selling.
Moderna, Inc. president Stephen Hoge reported routine equity compensation activity. He exercised 9,282 restricted stock units, which convert into common stock on a one-for-one basis, adding the same number of common shares.
In connection with this vesting, 4,488 shares were withheld at $47.19 per share to satisfy tax withholding obligations, a non‑market disposition. After these transactions, Hoge directly holds 1,483,848 shares of common stock and has 102,111 restricted stock units outstanding. Additional indirect common stock holdings are reported by a family trust and by Valhalla, LLC, with beneficial ownership of the trust shares disclaimed except for any pecuniary interest.